Seeing over the horizon - Targeting the endocannabinoid system for the treatment of ocular disease

Elizabeth A. Cairns; J. Thomas Toguri; Richard F. Porter; Anna Maria Szczesniak; Melanie E.M. Kelly

doi:10.1515/jbcpp-2015-0065

Seeing over the horizon - Targeting the endocannabinoid system for the treatment of ocular disease

Elizabeth A. Cairns, J. Thomas Toguri, Richard F. Porter, Anna Maria Szczesniak, Melanie E.M. Kelly

Medicine

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

Abstract

The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.

Original language	English
Pages (from-to)	253-265
Number of pages	13
Journal	Journal of Basic and Clinical Physiology and Pharmacology
Volume	27
Issue number	3
DOIs	https://doi.org/10.1515/jbcpp-2015-0065
Publication status	Published - May 1 2016

Bibliographical note

Funding Information:
The writing of this review was supported by a grant from the Canadian Institutes of Health Research (CIHR) MOP-97768 (M.E.M.K) and MOP-97769

Publisher Copyright:
© 2016 by De Gruyter.

ASJC Scopus Subject Areas

Physiology
Pharmacology
Drug Discovery

Access to Document

10.1515/jbcpp-2015-0065

Cite this

@article{c872bd8faf2c44fbb039033a5f61b67a,

title = "Seeing over the horizon - Targeting the endocannabinoid system for the treatment of ocular disease",

abstract = "The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.",

author = "Cairns, {Elizabeth A.} and Toguri, {J. Thomas} and Porter, {Richard F.} and Szczesniak, {Anna Maria} and Kelly, {Melanie E.M.}",

note = "Funding Information: The writing of this review was supported by a grant from the Canadian Institutes of Health Research (CIHR) MOP-97768 (M.E.M.K) and MOP-97769 Publisher Copyright: {\textcopyright} 2016 by De Gruyter.",

year = "2016",

month = may,

day = "1",

doi = "10.1515/jbcpp-2015-0065",

language = "English",

volume = "27",

pages = "253--265",

journal = "Journal of Basic and Clinical Physiology and Pharmacology",

issn = "0792-6855",

publisher = "Freund Publishing House Ltd",

number = "3",

}

TY - JOUR

T1 - Seeing over the horizon - Targeting the endocannabinoid system for the treatment of ocular disease

AU - Cairns, Elizabeth A.

AU - Toguri, J. Thomas

AU - Porter, Richard F.

AU - Szczesniak, Anna Maria

AU - Kelly, Melanie E.M.

N1 - Funding Information: The writing of this review was supported by a grant from the Canadian Institutes of Health Research (CIHR) MOP-97768 (M.E.M.K) and MOP-97769 Publisher Copyright: © 2016 by De Gruyter.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.

AB - The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.

UR - http://www.scopus.com/inward/record.url?scp=84969802185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969802185&partnerID=8YFLogxK

U2 - 10.1515/jbcpp-2015-0065

DO - 10.1515/jbcpp-2015-0065

M3 - Review article

C2 - 26565550

AN - SCOPUS:84969802185

SN - 0792-6855

VL - 27

SP - 253

EP - 265

JO - Journal of Basic and Clinical Physiology and Pharmacology

JF - Journal of Basic and Clinical Physiology and Pharmacology

IS - 3

ER -

Seeing over the horizon - Targeting the endocannabinoid system for the treatment of ocular disease

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this